Denali Therapeutics (DNLI) Competitors $25.05 -3.40 (-11.95%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends DNLI vs. CYTK, PRTA, RGNX, BMRN, MRNA, NBIX, TECH, PCVX, EXEL, and RVMDShould you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Cytokinetics (CYTK), Prothena (PRTA), REGENXBIO (RGNX), BioMarin Pharmaceutical (BMRN), Moderna (MRNA), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Vaxcyte (PCVX), Exelixis (EXEL), and Revolution Medicines (RVMD). These companies are all part of the "medical" sector. Denali Therapeutics vs. Cytokinetics Prothena REGENXBIO BioMarin Pharmaceutical Moderna Neurocrine Biosciences Bio-Techne Vaxcyte Exelixis Revolution Medicines Cytokinetics (NASDAQ:CYTK) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment. Do analysts rate CYTK or DNLI? Cytokinetics currently has a consensus target price of $83.67, indicating a potential upside of 66.60%. Denali Therapeutics has a consensus target price of $38.90, indicating a potential upside of 55.29%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts clearly believe Cytokinetics is more favorable than Denali Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytokinetics 0 Sell rating(s) 4 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.75Denali Therapeutics 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73 Does the MarketBeat Community prefer CYTK or DNLI? Cytokinetics received 350 more outperform votes than Denali Therapeutics when rated by MarketBeat users. Likewise, 79.60% of users gave Cytokinetics an outperform vote while only 67.77% of users gave Denali Therapeutics an outperform vote. CompanyUnderperformOutperformCytokineticsOutperform Votes80079.60% Underperform Votes20520.40% Denali TherapeuticsOutperform Votes45067.77% Underperform Votes21432.23% Is CYTK or DNLI more profitable? Denali Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -17,906.25%. Cytokinetics' return on equity of 0.00% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cytokinetics-17,906.25% N/A -50.21% Denali Therapeutics N/A -32.94%-30.04% Which has stronger valuation and earnings, CYTK or DNLI? Denali Therapeutics has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytokinetics$3.22M1,841.15-$526.24M-$5.38-9.33Denali Therapeutics$330.53M10.91-$145.22M-$2.76-9.08 Do insiders and institutionals hold more shares of CYTK or DNLI? 92.9% of Denali Therapeutics shares are owned by institutional investors. 3.4% of Cytokinetics shares are owned by company insiders. Comparatively, 7.9% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor CYTK or DNLI? In the previous week, Denali Therapeutics had 4 more articles in the media than Cytokinetics. MarketBeat recorded 28 mentions for Denali Therapeutics and 24 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.34 beat Denali Therapeutics' score of 0.26 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 7 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Denali Therapeutics 8 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, CYTK or DNLI? Cytokinetics has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. SummaryDenali Therapeutics beats Cytokinetics on 10 of the 18 factors compared between the two stocks. Ad WealthPressThe Tesla Trade Is Back In BusinessIf you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNLI vs. The Competition Export to ExcelMetricDenali TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.61B$2.91B$5.06B$8.67BDividend YieldN/A1.79%5.06%4.06%P/E Ratio-9.0840.4398.9217.12Price / Sales10.91217.681,205.7371.29Price / CashN/A178.0140.6936.36Price / Book2.734.096.325.87Net Income-$145.22M-$42.42M$119.47M$225.66M7 Day Performance-20.10%-10.63%-5.11%-1.34%1 Month Performance-9.44%-6.02%-3.21%1.00%1 Year Performance38.17%26.36%32.41%25.27% Denali Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNLIDenali Therapeutics4.3922 of 5 stars$25.05-12.0%$38.90+55.3%+38.2%$3.61B$330.53M-9.08364Insider SellingNews CoverageCYTKCytokinetics4.0656 of 5 stars$55.96-0.4%N/A+58.5%$6.60B$7.53M-10.40250Insider SellingPRTAProthena1.7428 of 5 stars$17.23-0.7%N/A-59.4%$926.63M$91.37M-6.95173Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageRGNXREGENXBIO4.377 of 5 stars$10.67+1.7%N/A-48.9%$528.65M$84.33M-2.12344Analyst ForecastNews CoverageGap UpBMRNBioMarin Pharmaceutical4.9905 of 5 stars$66.66+0.8%N/A-27.3%$12.70B$2.42B39.923,401Analyst ForecastInsider SellingNews CoverageMRNAModerna4.5631 of 5 stars$42.14-3.1%N/A-51.9%$16.22B$6.85B-7.245,600Analyst ForecastOptions VolumeGap DownNBIXNeurocrine Biosciences4.9632 of 5 stars$125.51-1.2%N/A+8.0%$12.71B$1.89B33.651,400TECHBio-Techne4.8317 of 5 stars$75.93+2.0%N/A+11.0%$12.06B$1.16B80.783,100Analyst UpgradePCVXVaxcyte3.3295 of 5 stars$96.63-2.8%N/A+73.3%$12.04BN/A-21.01160News CoverageHigh Trading VolumeEXELExelixis4.7676 of 5 stars$35.19-1.8%N/A+64.2%$10.05B$1.83B22.561,310Short Interest ↓RVMDRevolution Medicines3.5548 of 5 stars$58.13-2.0%N/A+159.4%$9.78B$11.58M-16.19443 Related Companies and Tools Related Companies Cytokinetics Competitors Prothena Competitors REGENXBIO Competitors BioMarin Pharmaceutical Competitors Moderna Competitors Neurocrine Biosciences Competitors Bio-Techne Competitors Vaxcyte Competitors Exelixis Competitors Revolution Medicines Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DNLI) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNLI Stock Alerts